X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-07-03 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $68.15 | -10,903 | 39,744 | -22% | -$743,039 | ||||||
| D | 2025-07-02 | INCY | Incyte Corp | Denton Sheila A. | EVP, GC | S - Sale+OE | $68.61 | -599 | 26,504 | -2% | -$41,097 | |||||
2025-07-03 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale | $68.15 | -8,617 | 37,701 | -19% | -$587,275 | ||||||
2025-07-01 | NOTV | Inotiv, Inc. | Neff R Matthew | Dir | S - Sale | $1.81 | -2,000 | 151,102 | -1% | -$3,621 | ||||||
| D | 2025-06-03 | INCY | Incyte Corp | Denton Sheila A. | EVP, GC | S - Sale+OE | $68.00 | -1,795 | 26,504 | -6% | -$122,060 | |||||
2025-06-02 | NOTV | Inotiv, Inc. | Neff R Matthew | Dir | S - Sale | $2.62 | -2,000 | 153,102 | -1% | -$5,246 | ||||||
| M | 2025-05-30 | INCY | Incyte Corp | Tray Thomas | Principal Accounting Officer | S - Sale | $65.38 | -1,614 | 22,003 | -7% | -$105,516 | |||||
2025-05-15 | CRL | Charles River Laboratories International, Inc. | Massaro George | Dir | S - Sale | $137.58 | -140 | 5,575 | -2% | -$19,260 | ||||||
2025-05-14 | CRL | Charles River Laboratories International, Inc. | Massaro George | Dir | S - Sale | $140.74 | -140 | 5,715 | -2% | -$19,703 | ||||||
2025-05-13 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $145.41 | -500 | 19,513 | -2% | -$72,705 | ||||||
2025-05-15 | OABI | Omniab, Inc. | Cochran Jennifer R. | Dir | P - Purchase | $1.52 | +30,000 | 145,274 | +26% | +$45,600 | ||||||
2025-05-14 | OABI | Omniab, Inc. | Love Steven | Dir | P - Purchase | $1.46 | +25,000 | 38,333 | +188% | +$36,500 | ||||||
2025-05-12 | OABI | Omniab, Inc. | Higgins John L | Dir | P - Purchase | $1.44 | +65,000 | 2,831,887 | +2% | +$93,600 | ||||||
2025-05-12 | NRC | National Research Corp | Beans Patrick E | 10% | P - Purchase | $13.59 | +2,500 | 35,003 | +8% | +$33,974 | ||||||
| D | 2025-04-24 | MEDP | Medpace Holdings, Inc. | Davenport Fred B Jr | Dir | S - Sale+OE | $301.82 | -1,712 | 4,998 | -26% | -$516,716 | |||||
| D | 2025-04-07 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | S - Sale+OE | $2.00 | -19,382 | 3,796,236 | -1% | -$38,764 | |||||
| D | 2025-04-07 | OABI | Omniab, Inc. | Berkman Charles S | GC | S - Sale+OE | $2.00 | -7,206 | 363,212 | -2% | -$14,412 | |||||
| D | 2025-04-07 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | S - Sale+OE | $2.00 | -7,206 | 223,828 | -3% | -$14,412 | |||||
2025-04-01 | NOTV | Inotiv, Inc. | Coelho Mary Theresa | Dir | S - Sale | $2.35 | -5,500 | 74,303 | -7% | -$12,916 | ||||||
| D | 2025-04-01 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | S - Sale+OE | $2.37 | -11,963 | 217,492 | -5% | -$28,352 | |||||
2025-03-21 | OABI | Omniab, Inc. | Higgins John L | Dir | P - Purchase | $2.28 | +4,000 | 2,766,887 | 0% | +$9,120 | ||||||
2025-03-20 | OABI | Omniab, Inc. | Higgins John L | Dir | P - Purchase | $2.35 | +125,750 | 2,762,887 | +5% | +$295,513 | ||||||
2025-03-18 | MXCT | Maxcyte, Inc. | Soleymannezhad Ali | Chief Commercial Officer | S - Sale | $3.18 | -1,211 | 59,439 | -2% | -$3,850 | ||||||
2025-03-18 | MXCT | Maxcyte, Inc. | Sandoval David I. | GC | S - Sale | $3.18 | -353 | 64,219 | -1% | -$1,122 | ||||||
2025-03-18 | MXCT | Maxcyte, Inc. | Swirsky Douglas J | CFO | S - Sale | $3.18 | -6,939 | 111,811 | -6% | -$22,061 | ||||||
2025-03-14 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $67.69 | -19,807 | 33,567 | -37% | -$1,340,656 | ||||||
| D | 2025-03-04 | INCY | Incyte Corp | Denton Sheila A. | EVP, GC | S - Sale+OE | $69.99 | -599 | 25,848 | -2% | -$41,924 | |||||
| D | 2025-02-26 | INCY | Incyte Corp | Denton Sheila A. | EVP, GC | S - Sale+OE | $74.07 | -14,069 | 25,848 | -35% | -$1,042,136 | |||||
2025-02-27 | MEDP | Medpace Holdings, Inc. | Ewald Stephen P | GC, Corp. Secy. | P - Purchase | $326.11 | +2 | 13,343 | 0% | +$652 | ||||||
| D | 2025-02-24 | MEDP | Medpace Holdings, Inc. | Carley Brian T | Dir | S - Sale+OE | $345.59 | -4,003 | 26,032 | -13% | -$1,383,397 | |||||
2025-02-20 | CRL | Charles River Laboratories International, Inc. | Foster James C | COB, Pres, CEO | P - Purchase | $165.01 | +6,075 | 250,710 | +2% | +$1,002,436 | ||||||
2025-02-20 | CRL | Charles River Laboratories International, Inc. | Girshick Birgit | Corporate EVP, COO | P - Purchase | $164.63 | +1,514 | 55,058 | +3% | +$249,250 | ||||||
2025-02-20 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $162.50 | -4,400 | 20,013 | -18% | -$715,000 | ||||||
2025-02-18 | NOTV | Inotiv, Inc. | Freeman Jeffrey Brennan | VP-Finance, Corp. Controller | S - Sale | $4.05 | -1,339 | 27,478 | -5% | -$5,416 | ||||||
2025-02-18 | NOTV | Inotiv, Inc. | Taylor Beth | CFO | S - Sale | $4.01 | -4,370 | 108,368 | -4% | -$17,507 | ||||||
2025-02-18 | NOTV | Inotiv, Inc. | Sagartz John E | Chief Strategy Officer | S - Sale | $3.94 | -2,113 | 707,816 | 0% | -$8,316 | ||||||
2025-02-18 | NOTV | Inotiv, Inc. | Leasure Robert Jr. | Pres, CEO | S - Sale | $3.82 | -73,617 | 1,061,592 | -6% | -$281,136 | ||||||
| D | 2025-02-19 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | S - Sale+OE | $3.67 | -7,255 | 206,211 | -3% | -$26,626 | |||||
| DM | 2025-02-18 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | S - Sale+OE | $3.67 | -33,486 | 3,779,160 | -1% | -$123,033 | |||||
| DM | 2025-02-18 | OABI | Omniab, Inc. | Berkman Charles S | GC | S - Sale+OE | $3.68 | -15,470 | 356,876 | -4% | -$56,857 | |||||
| D | 2024-12-03 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | P - Purchase | $200.58 | +1,275 | 28,724 | +5% | +$255,740 | |||||
2025-01-31 | NOTV | Inotiv, Inc. | Leasure Robert Jr. | Pres, CEO | S - Sale | $4.15 | -22,700 | 1,135,209 | -2% | -$94,298 | ||||||
2025-01-31 | NOTV | Inotiv, Inc. | Taylor Beth | CFO | S - Sale | $4.47 | -2,054 | 112,738 | -2% | -$9,171 | ||||||
2025-01-31 | NOTV | Inotiv, Inc. | Sagartz John E | Chief Strategy Officer | S - Sale | $4.48 | -2,118 | 709,929 | 0% | -$9,479 | ||||||
| M | 2025-01-31 | NOTV | Inotiv, Inc. | Krupp Jeffrey Arthur | CHRO | S - Sale | $4.42 | -2,508 | 28,557 | -8% | -$11,096 | |||||
| D | 2025-01-27 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.65 | -3,000 | 141,950 | -2% | -$13,935 | |||||
2025-01-21 | OABI | Omniab, Inc. | Berkman Charles S | GC | S - Sale | $3.24 | -25,489 | 343,190 | -7% | -$82,584 | ||||||
2025-01-21 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | S - Sale | $3.24 | -15,526 | 212,720 | -7% | -$50,304 | ||||||
2025-01-21 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | S - Sale | $3.24 | -41,811 | 3,749,639 | -1% | -$135,468 | ||||||
| D | 2025-01-21 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale+OE | $72.69 | -12,352 | 66,967 | -16% | -$897,867 | |||||
2025-01-13 | MXCT | Maxcyte, Inc. | Sandoval David I. | GC | S - Sale | $4.54 | -4,466 | 41,447 | -10% | -$20,272 | ||||||
| D | 2024-12-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.01 | -3,000 | 141,950 | -2% | -$12,021 | |||||
2024-12-19 | NOTV | Inotiv, Inc. | Landman David | Dir | P - Purchase | $4.25 | +23,529 | 176,851 | +15% | +$99,998 | ||||||
| M | 2024-12-13 | INCY | Incyte Corp | Tray Thomas | Principal Accounting Officer | S - Sale | $69.98 | -1,300 | 23,312 | -5% | -$90,968 | |||||
2024-12-10 | NOTV | Inotiv, Inc. | Beattie John Gregory | COO | P - Purchase | $4.75 | +30,000 | 161,761 | +23% | +$142,500 | ||||||
| D | 2024-12-09 | OABI | Omniab, Inc. | Berkman Charles S | GC | S - Sale+OE | $4.13 | -8,022 | 323,385 | -2% | -$33,131 | |||||
| D | 2024-12-09 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | S - Sale+OE | $4.13 | -13,634 | 3,714,447 | 0% | -$56,308 | |||||
| D | 2024-12-09 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | S - Sale+OE | $4.13 | -23,871 | 200,661 | -11% | -$98,587 | |||||
| DM | 2024-12-06 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $3.78 | -3,000 | 141,950 | -2% | -$11,328 | |||||
2024-12-10 | NOTV | Inotiv, Inc. | Brown Nigel | Dir | P - Purchase | $4.26 | +7,500 | 65,537 | +13% | +$31,950 | ||||||
2024-12-06 | NOTV | Inotiv, Inc. | Harrington Michael J | Dir | P - Purchase | $3.98 | +10,000 | 37,500 | +36% | +$39,822 | ||||||
2024-12-06 | NOTV | Inotiv, Inc. | Landman David | Dir | P - Purchase | $4.14 | +100,000 | 153,322 | +188% | +$414,000 | ||||||
2024-11-29 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale | $75.38 | -6,043 | 30,658 | -16% | -$455,544 | ||||||
2024-11-07 | CRL | Charles River Laboratories International, Inc. | Wallman Richard F | Dir | S - Sale | $216.17 | -7,621 | 12,386 | -38% | -$1,647,418 | ||||||
| D | 2024-11-06 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $79.68 | -3,680 | 58,042 | -6% | -$293,210 | |||||
| D | 2024-11-01 | MXCT | Maxcyte, Inc. | Erck Stanley C | Dir | S - Sale+OE | $3.72 | -47,689 | 269,118 | -15% | -$177,403 | |||||
| D | 2024-10-28 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $3.72 | -3,000 | 141,950 | -2% | -$11,166 | |||||
| DM | 2024-10-01 | MXCT | Maxcyte, Inc. | Erck Stanley C | Dir | S - Sale+OE | $3.75 | -47,689 | 269,118 | -15% | -$178,752 | |||||
| D | 2024-09-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $3.82 | -3,000 | 141,950 | -2% | -$11,460 | |||||
| M | 2024-09-12 | INCY | Incyte Corp | Tray Thomas | Principal Accounting Officer | S - Sale | $63.11 | -954 | 24,443 | -4% | -$60,209 | |||||
2024-09-12 | INCY | Incyte Corp | Dickinson Jonathan Elliott | EVP, GM, Europe | S - Sale | $62.36 | -8,450 | 36,390 | -19% | -$526,948 | ||||||
| DM | 2024-09-03 | MXCT | Maxcyte, Inc. | Erck Stanley C | Dir | S - Sale+OE | $4.02 | -47,689 | 269,118 | -15% | -$191,655 | |||||
2024-08-27 | IQV | Iqvia Holdings Inc. | Sherbet Eric | See Remarks | S - Sale | $246.33 | -1,300 | 19,536 | -6% | -$320,229 | ||||||
| D | 2024-08-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.28 | -3,000 | 141,950 | -2% | -$12,840 | |||||
| DM | 2024-08-22 | MEDP | Medpace Holdings, Inc. | Kraft Robert O. | Dir | S - Sale+OE | $390.73 | -8,127 | 520 | -94% | -$3,175,463 | |||||
2024-08-12 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale | $60.63 | -11,608 | 90,011 | -11% | -$703,793 | ||||||
2024-08-08 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $199.36 | -1,780 | 22,521 | -7% | -$354,861 | ||||||
| DM | 2024-08-01 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, GLOBAL SALES | S - Sale+OE | $4.44 | -33,333 | 25,000 | -57% | -$148,135 | |||||
2024-08-01 | CRL | Charles River Laboratories International, Inc. | Foster James C | COB, Pres, CEO | S - Sale | $250.00 | -25,000 | 238,854 | -9% | -$6,250,000 | ||||||
| D | 2024-07-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.75 | -3,000 | 141,950 | -2% | -$14,238 | |||||
2024-07-25 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale | $70.00 | -15,571 | 36,701 | -30% | -$1,089,970 | ||||||
2024-07-22 | FOXO | Foxo Technologies Inc. | Kr8 Ai Inc. | 10% | S - Sale | $0.25 | -1,300,000 | 0 | -100% | -$325,000 | ||||||
2024-07-22 | FOXO | Foxo Technologies Inc. | White Mark Brian | Interim CEO, 10% | S - Sale | $0.25 | -1,300,000 | 0 | -100% | -$325,000 | ||||||
2024-07-22 | FOXO | Foxo Technologies Inc. | Ward Martin Christopher | Interim CFO, 10% | S - Sale | $0.25 | -1,300,000 | 0 | -100% | -$325,000 | ||||||
| D | 2024-07-16 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $64.19 | -1,306 | 58,042 | -2% | -$83,832 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |